Delaware · Contract for Care
Delaware Pain Treatment Agreements: State Requirements
Delaware requires a signed treatment agreement for covered chronic-pain opioid treatment. That requirement does not make every office-written condition a state mandate.
What is mandatory, and when?
| Issue | Delaware baseline | Boundary to check |
|---|---|---|
| Covered chronic pain | Uniform regulation §9.3 defines chronic pain as continuous or nearly continuous pain lasting more than three months beyond the usual course of disease or healing. | The definition concerns pain duration, not a requirement to wait until three months of opioid prescriptions. |
| Signed agreement | §9.8.4 requires a treatment agreement. Under §9.3 it is written, signed by the practitioner and patient or proxy, and retained in the medical record. | The definition lists possible terms at practitioner discretion; it does not prescribe one universal form. |
| Testing | §9.8.3 requires fluid drug screening at least every six months for covered chronic-pain patients. | The minimum exists independently of whether the agreement repeats it. Ask why additional frequency or a particular test is needed and who pays. |
| Prescription monitoring | §9.8.1–2 requires PMP checks at least every six months, more often when clinically indicated, with benzodiazepine prescribing, and when misuse risk or specified warning signs arise. | This does not itself mandate an office visit for every refill. |
| Assessment and alternatives | §9.8 requires a risk assessment and documentation of alternative treatments tried and their adequacy; concurrent care for comorbidities should be pursued when clinically feasible. | Documenting alternatives is not a blanket requirement to purchase every service from the prescribing office. |
| Consent and follow-up | §9.8 incorporates §9.6: clinical evaluation, documented discussion, signed informed consent about specified risks, and periodic follow-up and treatment review. | Consent to risks and a treatment agreement serve different purposes. Ask how each is documented. |
| High-risk agreement terms | Medical Board §18.4 requires a written agreement for the specified high-risk/history group addressing requested screening, refill number/frequency, discontinuation reasons, and one practitioner/one pharmacy where possible. | Do not describe these terms as universally optional or universally mandatory: professional scope and the risk/history trigger matter. |
| Acute supply limits | §9.5 generally limits an adult’s first outpatient acute-pain opioid prescription to seven days, and prescriptions to minors to seven days. A documented acute clinical exception is available with specified safeguards. | This is not a blanket seven-day limit on all adult chronic-pain prescriptions. |
| Exemptions | §9.9 exempts hospice, active cancer treatment, cancer-related pain, terminal/palliative care, and hospital care during admission including discharge prescriptions of seven days or less. | §9.7 separately provides narrow exceptions to §9.6. An exemption from §9 does not erase every other applicable law or professional duty. |
Where office policy begins
For covered patients, an agreement and minimum monitoring are legal requirements. A universal first-visit prescribing ban, no weekend refill processing, an automatic lost-prescription denial, a specified pill-count deadline, or a rule requiring all adjunct services in-house is not stated as a universal requirement in the sections reviewed. Other law, clinical circumstances, or payer rules may matter. An added term is not automatically unlawful; the question is what actually authorizes it, how exceptions work, and whether it fits the individual patient.
Individualized care remains part of the standard
Medical Board §18 recognizes legitimate pain treatment, concerns about undertreatment, and evaluation based on the clinical record rather than medication quantity or duration alone. Its treatment-plan and review provisions call for attention to individual needs and function. CDC guidance is clinical guidance, not an independent Delaware statute; it cautions against rigid application and abrupt discontinuation absent a life-threatening issue.
Questions to take to the office
- Which provision requires this exact condition for my situation?
- Which parts are the practice’s policy, and can I receive the current dated version?
- How are testing costs, outside treatments, exceptions and disputed results handled?
- What plan supports safe continuity if treatment changes?
Primary sources
- Uniform Controlled Substances Act Regulations, §§9.3–9.9 (official PDF)
- Delaware Medical Board Regulation 1700, §18, April 2025 final rule publication
- CDC recommendations and guiding principles
This is an evidence comparison, not a finding about a practitioner’s compliance or advice to change medication.
Public sources checked October 13, 2026. A location listing is not a recommendation, a promise of prescribing, or confirmation of new-patient availability. Public document availability does not establish current use for a particular patient. Compare the version supplied by your care team.
CONTRACT FOR CARE · RIGHTS, CONSENT & GOVERNMENT POWER
Our Legal Case
A patient’s need for medicine should not become the pressure used to obtain a criminal admission. Examine compulsory disclosures, penalties for silence, coerced rights waivers, and the circumstances behind the signature.
Use this state record to trace the legal requirement, then compare it with the terms an office adds. The full work explains the constitutional case, consent analysis, evidence needed, and protections to demand.
Apply the constitutional and consent review to this record
- Government responsibility: Which law, binding rule, agency instruction, or public-provider policy requires the particular disclosure or consequence? Separate it from provider-added terms.
- Potential criminal admission: Identify the exact spoken answer, written history, certification, or explanation and the real criminal risk it creates.
- Penalty for silence: Record what happens if the patient invokes the privilege or refuses a rights waiver, including denial, discharge, or interruption of treatment.
- Consent and pressure: Preserve the circumstances of signing, severity of pain, accessible alternatives, and whether the patient could honestly accept the prospective obligations.
- Criminal-use protection: Identify legally sufficient immunity and limits on use of both the answer and evidence derived from it. A privacy assurance is a separate protection.
Read the precedents, evidence framework, clause review, and remedies and reform demands. The work develops a proposed constitutional challenge; applying it to a particular condition requires its facts and legal authority.